国药股份 (600511)
China National Medicines Corporation Ltd.
K-Line Chart
No K-line data available
Company NameSinopharm Group Co., Ltd.
Listing Date2002-11-27
Issue Price5RMB
Registered Capital75450.299810k RMB
Legal RepresentativeTian Guotao
Registered AddressFloors 6-9, West Tower, Building 7, No. 8 Yard, Yongdingmen West Binhe Road, Dongcheng District, Beijing
IndustryPharmaceutical Commerce
Main BusinessOrganize drug production; sales of chemical APIs, western medicine preparations, biochemical drugs, biological products, and traditional Chinese patent medicines.
Company ProfileSinopharm Group Co., Ltd. was formerly known as China National Pharmaceutical Corporation. It was initiated and established by China National Pharmaceutical Group Corporation on December 21, 1999. In November 2002, the company was listed on the Shanghai Stock Exchange (Stock Code: 600511) with a registered capital of 766.93 million yuan. Sinopharm Group is affiliated with Sinopharm Group Co., Ltd., China's largest distributor of pharmaceuticals and healthcare products, and is a third-tier subsidiary of China National Pharmaceutical Group Corporation.
Focusing on the core positioning of building a "specialized brand in the characteristic pharmaceutical and health industry," Sinopharm Group deeply cultivates the Beijing regional market and radiates to the national pharmaceutical market. It oversees 11 wholly-owned or controlled subsidiaries and 4 equity-holding companies. Its business formats cover pharmaceutical commerce, pharmaceutical industry, logistics and warehousing, import and bonded services, and other operations. Simultaneously, leveraging capital and innovation drivers, it extends the upstream and downstream industry chain and deploys in the national characteristic healthcare market. In 2017, Sinopharm Group achieved operating revenue of 36.3 billion yuan, ranking first among wholesale enterprises in the Beijing regional pharmaceutical distribution industry.
Stock Details
1. Key Indicators
- Total Shares(W): 75450.30
- Circulating A-Shares(W): 55334.64
- Earnings Per Share(RMB): 1.9778
- Net Assets Per Share(RMB): 23.9132
- Operating Revenue(W RMB): 3938130.14
- Total Profit(W RMB): 193374.25
- **Net Profit Attributable to Parent(W RMB) **: 149226.53
- Net Profit Growth Rate(%): 0.74
- Weighted Return on Equity(%): 8.5000
- Operating Cash Flow Per Share(RMB): -2.7180
- Undistributed Profit Per Share(RMB): 18.9248
- Capital Reserve Per Share(RMB): 3.1131
2. Main Business
The main business covers:
- Pharmaceutical Distribution
- Pharmaceutical Manufacturing
- Pharmaceutical Logistics
3. Company Basic Information
- Company Name: Sinopharm Group Co., Ltd.
- Listing Date: 2002-11-27
- Industry: Pharmaceutical & Healthcare - Pharmaceutical Commerce
- Address: 6-9F, West Tower, Building 7, No. 8 Yongdingmen Xibinhe Road, Dongcheng District, Beijing
- Website: http://www.sinopharm.com/
- Company Profile: The company was established with the approval of the State Economic and Trade Commission. China National Pharmaceutical Group Co., Ltd. acted as the main sponsor, jointly established with Sinopharm Group Shanghai Medical Devices Co., Ltd., Tianjin Qiyu Medical Devices Co., Ltd., Guangzhou Nanfang Medical Devices Company, and Beijing Renkang Medical Devices Business Department.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Sinopharm Group Co., Ltd. | Corporate Legal Person | 21168.52 | 38.26 |
| 2 | National Social Security Fund 113 Portfolio | Social Security Fund | 2281.76 | 4.12 |
| 3 | New China Life Insurance Co., Ltd. - Traditional - General Insurance Product - 018L-CT001 Shanghai | Insurance | 2033.20 | 3.67 |
| 4 | Basic Pension Insurance Fund 802 Portfolio | Social Security Fund | 2031.80 | 3.67 |
| 5 | New China Life Insurance Co., Ltd. - Dividend - Individual Dividend - 018L-FH002 Shanghai | Insurance | 1333.30 | 2.41 |
| 6 | Beijing Kangen Pharmaceutical Co., Ltd. | Corporate Legal Person | 1023.62 | 1.85 |
| 7 | Beijing Changxin Yida Investment Advisory Co., Ltd. | Corporate Legal Person | 724.26 | 1.31 |
| 8 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 689.81 | 1.25 |
| 9 | New China Life Insurance Co., Ltd. - Dividend - Group Dividend - 018L-FH001 Shanghai | Insurance | 583.84 | 1.06 |
| 10 | CSI 500 Exchange Traded Open End Index Securities Investment Fund | Fund | 550.70 | 1.00 |
5. Concept Sectors
- Biological Vaccine
- Cold Chain Logistics
- Margin Trading & Securities Lending
- Heavily Held by Insurance
- Low P/E Ratio
- High-Performing Stock
- Heavily Held by Social Security Funds
- Pension Fund
- MSCI Mid Cap
- High Accounts Receivable
- Small Cap Value
- SZSE Value Index
- CSI Central SOEs
- SSE Mixed-Ownership Reform
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information